PT-141 (Bremelanotide) is a synthetic peptide and melanocortin receptor agonist.
🔬 Studied for: Sexual-Function Research
💊 Also studied for: Melanocortin-Receptor Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
PT-141 (Bremelanotide) is a synthetic peptide and melanocortin receptor agonist. It holds FDA approval under the brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the better-documented peptides in this category.
PT-141 acts as an agonist at melanocortin 4 receptors (MC4R) in the central nervous system, a pathway distinct from the vascular mechanism used by PDE5 inhibitors such as sildenafil, which is why it has been studied specifically for centrally-mediated sexual arousal research.
These are effects PT-141 (Bremelanotide) has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
PT-141's approved indication is grounded in Phase 3 clinical trials studying its effects on sexual desire in women, and it remains the primary reference compound for melanocortin-pathway research in this area.
Beyond its approved use, PT-141 is studied more broadly as a research tool for examining MC4R signaling, an area that overlaps with appetite and energy-balance research given MC4R's role in those pathways.
The FDA-approved clinical dose for Vyleesi is 1.75mg by subcutaneous autoinjector, administered as needed at least 45 minutes before anticipated activity, per its prescribing information — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not provide dosing recommendations. PT-141 (Bremelanotide) is sold for laboratory research use only and is not intended for human consumption.
In its FDA-approved clinical use, documented side effects include nausea, flushing, headache, and transient increases in blood pressure, detailed in the Vyleesi prescribing information. Research-grade material sourced outside that regulated supply chain has not undergone the same quality controls.
No. PT-141 (Bremelanotide) is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Sexual-Function Research — PT-141's approved indication is grounded in Phase 3 clinical trials studying its effects on sexual desire in women, and it remains the primary reference compound for melanocortin-pathway research in this area.
In the US, UK, Canada and Australia, PT-141 (Bremelanotide) is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
PT-141/Bremelanotide's clinical trial data and prescribing information are available via the FDA and are also indexed on PubMed under "Bremelanotide melanocortin receptor."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.